QDEL
BEARISH
$12.71
Live
QuidelOrtho Corporation · NASDAQ
Target $30.83
(+142.6%)
$11.61
52W Range
$38.99
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 18, 2026
Market cap
$865.32M
P/E
N/A
ROE
-46.1%
Profit margin
-41.5%
Debt/Equity
1.49
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
QuidelOrtho exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a technical trend score of 0/100. Despite appearing 'cheap' on a Price-to-Book (0.45) and Price-to-Sales (0.32) basis, the company suffers from negative profit margins (-41.45%) and a catastrophic 5-year price decline of 89.6%. The disconnect between the bullish analyst target ($30.83) and the deteriorating fundamental health suggests a classic value trap. The lack of revenue growth (2.2%) and negative ROE (-46.15%) further undermine any recovery thesis.
Key Strengths
Deeply undervalued Price-to-Book ratio (0.45)
Low Price-to-Sales ratio (0.32)
Strong Gross Margin (46.81%)
Current Ratio of 1.50 indicates short-term liquidity
Significant positive gap between current price and analyst target price
Key Risks
Critically low Piotroski F-Score (2/9) indicating fundamental weakness
Severe negative profit margins (-41.45%)
Extreme bearish price momentum (1Y change -49.5%, 6M change -54.8%)
Stagnant revenue growth (2.2% YoY)
High Debt/Equity ratio (1.49) coupled with negative ROE
AI Fair Value Estimate
Based on comprehensive analysis
$16.5
+29.8% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
25
Weak
65
30
10
20
0
AI Verdict
High-Risk Value Trap
Key drivers: Piotroski F-Score of 2/9, Negative Profitability, Extreme Price Decay, Stagnant Growth
Confidence
90%
Value
65/100
Trades at a massive discount to book value, but earnings are currently non-existent.
Positives
- P/B 0.45
- P/S 0.32
- Forward P/E 4.39
Watchpoints
- Negative trailing earnings
- Low quality of assets implied by P/B
Future
30/100
Growth metrics are anemic and fail to justify a recovery without a major pivot.
Positives
- Bullish analyst price targets
Watchpoints
- YoY EPS Growth -27%
- Revenue growth only 2.2%
Past
10/100
Long-term price performance is catastrophic.
Positives
No standout positives identified.
Watchpoints
- 5Y Change -89.6%
- 1Y Change -49.5%
- Consistent earnings misses
Health
20/100
Deterministic health scores indicate a company in significant financial decline.
Positives
- Current Ratio 1.50
Watchpoints
- Piotroski F-Score 2/9
- ROE -46.15%
- Debt/Equity 1.49
Dividend
0/100
No income component to offset capital risk.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 Dividend Strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$12.71
Analyst Target
$30.83
Upside/Downside
+142.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for QDEL and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
QDEL
QuidelOrtho Corporation
Primary
|
-89.6% | -86.0% | -49.5% | -54.8% | -25.4% | -8.2% |
|
ABUS
Arbutus Biopharma Corporation
Peer
|
+34.8% | +48.0% | +34.4% | +0.9% | +3.2% | +6.6% |
|
INMD
InMode Ltd.
Peer
|
-67.3% | -61.5% | -4.0% | -11.4% | +3.0% | -1.9% |
|
FTRE
Fortrea Holdings Inc.
Peer
|
-68.8% | -68.8% | +45.4% | -12.7% | +4.8% | -0.7% |
|
MNKD
MannKind Corporation
Peer
|
-36.3% | -32.0% | -40.8% | -46.3% | -1.1% | +6.6% |
QDE
QuidelOrtho Corporation
Primary
5Y
-89.6%
3Y
-86.0%
1Y
-49.5%
6M
-54.8%
1M
-25.4%
1W
-8.2%
ABU
Arbutus Biopharma Corporation
Peer
5Y
+34.8%
3Y
+48.0%
1Y
+34.4%
6M
+0.9%
1M
+3.2%
1W
+6.6%
INM
InMode Ltd.
Peer
5Y
-67.3%
3Y
-61.5%
1Y
-4.0%
6M
-11.4%
1M
+3.0%
1W
-1.9%
FTR
Fortrea Holdings Inc.
Peer
5Y
-68.8%
3Y
-68.8%
1Y
+45.4%
6M
-12.7%
1M
+4.8%
1W
-0.7%
MNK
MannKind Corporation
Peer
5Y
-36.3%
3Y
-32.0%
1Y
-40.8%
6M
-46.3%
1M
-1.1%
1W
+6.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
4.39
PEG Ratio
2.06
P/B Ratio
0.45
P/S Ratio
0.32
EV/Revenue
1.3
EV/EBITDA
6.32
Market Cap
$865.32M
Profitability
Profit margins and return metrics
Profit Margin
-41.45%
Operating Margin
4.01%
Gross Margin
46.81%
ROE
-46.15%
ROA
1.27%
Growth
Revenue and earnings growth rates
Revenue Growth
+2.2%
Earnings Growth
N/A
Q/Q Revenue Growth
+2.23%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.49
Moderate
Current Ratio
1.5
Good
Quick Ratio
0.77
Poor
Cash/Share
$2.5
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.7B
Gross Margin
44.3%
Op. Margin
-5.2%
Net Margin
-18.1%
Total Assets
$5.8B
Liabilities
$3.8B
Equity
$1.9B
Debt/Equity
2.00x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
66%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-11
$0.46
+8.8% surprise
2025-11-05
$0.8
+71.6% surprise
2025-08-05
$-3.77
-267.5% surprise
Healthcare Sector Comparison
Comparing QDEL against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-46.15%
This Stock
vs
-100.15%
Sector Avg
-53.9%
(Below Avg)
Profit Margin
-41.45%
This Stock
vs
-13.63%
Sector Avg
+204.2%
(Superior)
Debt to Equity
1.49
This Stock
vs
3.22
Sector Avg
-53.8%
(Less Debt)
Revenue Growth
2.2%
This Stock
vs
121.05%
Sector Avg
-98.2%
(Slower)
Current Ratio
1.5
This Stock
vs
4.55
Sector Avg
-67.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
QDEL
QuidelOrtho Corporation
|
BEARISH | $865.32M | - | -46.1% | -41.5% | $12.71 | |
|
ABUS
Arbutus Biopharma Corporation
|
BEARISH | $872.03M | - | -38.5% | -237.9% | $4.53 | Compare |
|
INMD
InMode Ltd.
|
NEUTRAL | $857.24M | 9.46 | 13.5% | 25.3% | $13.53 | Compare |
|
FTRE
Fortrea Holdings Inc.
|
BEARISH | $877.03M | - | -102.4% | -36.2% | $9.38 | Compare |
|
MNKD
MannKind Corporation
|
BEARISH | $846.1M | 137.0 | -% | 1.7% | $2.74 | Compare |
QDEL
QuidelOrtho Corporation
BEARISH
Mkt Cap
$865M
P/E
-
ROE
-46.1%
Price
$12.71
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-27 | BUSKY JOSEPH M | Chief Financial Officer | Stock Award | 4,925 | - |
| 2026-03-27 | BUSKY JOSEPH M | Chief Financial Officer | Option Exercise | 4,925 | $72,792 |
| 2026-02-13 | STROBECK MATTHEW | Director | Purchase | 10,000 | $239,586 |
| 2026-02-13 | BUSKY JOSEPH M | Chief Financial Officer | Purchase | 3,370 | $79,742 |
| 2026-02-13 | BUSKY JOSEPH M | Chief Financial Officer | Purchase | 3,370 | $79,742 |
| 2026-02-13 | BLASER BRIAN J | Chief Executive Officer | Purchase | 10,540 | $248,661 |
| 2026-02-06 | BUSKY JOSEPH M | Chief Financial Officer | Stock Award | 5,968 | - |
| 2026-02-06 | BUSKY JOSEPH M | Chief Financial Officer | Option Exercise | 5,968 | $173,669 |
| 2026-02-06 | HODGES MICHELLE A | Officer | Stock Award | 3,198 | - |
| 2026-02-06 | HODGES MICHELLE A | Officer | Option Exercise | 3,198 | $93,062 |
| 2026-01-30 | HODGES MICHELLE A | Officer | Stock Award | 3,424 | - |
| 2026-01-30 | HODGES MICHELLE A | Officer | Option Exercise | 1,610 | $43,744 |
| 2026-01-30 | MCLELLAN PHILIP D. | Chief Operating Officer | Stock Award | 4,617 | - |
| 2026-01-30 | MCLELLAN PHILIP D. | Chief Operating Officer | Option Exercise | 1,127 | $30,621 |
| 2026-01-29 | BUSKY JOSEPH M | Chief Financial Officer | Stock Award | 8,425 | - |
BUSKY JOSEPH M
Chief Financial Officer
2026-03-27
4,925 shares
BUSKY JOSEPH M
Chief Financial Officer
2026-03-27
4,925 shares
·
$72,792
STROBECK MATTHEW
Director
2026-02-13
10,000 shares
·
$239,586
BUSKY JOSEPH M
Chief Financial Officer
2026-02-13
3,370 shares
·
$79,742
BUSKY JOSEPH M
Chief Financial Officer
2026-02-13
3,370 shares
·
$79,742
BLASER BRIAN J
Chief Executive Officer
2026-02-13
10,540 shares
·
$248,661
BUSKY JOSEPH M
Chief Financial Officer
2026-02-06
5,968 shares
BUSKY JOSEPH M
Chief Financial Officer
2026-02-06
5,968 shares
·
$173,669
HODGES MICHELLE A
Officer
2026-02-06
3,198 shares
HODGES MICHELLE A
Officer
2026-02-06
3,198 shares
·
$93,062
HODGES MICHELLE A
Officer
2026-01-30
3,424 shares
HODGES MICHELLE A
Officer
2026-01-30
1,610 shares
·
$43,744
MCLELLAN PHILIP D.
Chief Operating Officer
2026-01-30
4,617 shares
MCLELLAN PHILIP D.
Chief Operating Officer
2026-01-30
1,127 shares
·
$30,621
BUSKY JOSEPH M
Chief Financial Officer
2026-01-29
8,425 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
8-K
10-K
8-K
8-K
8-K
10-Q
8-K
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
6 analysts
UBS
2026-04-10
Neutral
Neutral
Citigroup
2026-02-12
Neutral
Neutral
UBS
2026-01-21
Neutral
Neutral
JP Morgan
2025-11-07
Underweight
Underweight
UBS
2025-11-06
Neutral
Neutral
Past News Coverage
Recent headlines mentioning QDEL from our newsroom.
Newest → oldest
No matching news yet.